Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Romosozumab From Amgen Inc (AMGN) Shows Positive Results In Osteoporosis

Romosozumab (AKA romo) from Amgen Inc (NASDAQ:AMGN) and Belgium-based UCB, which is in its Phase III FRAME study is yet to achieve any regulatory approval from the FDA until some time next year. However, the study, which involved more than 7,000 women with osteoporosis, revealed that it is close to meeting both primary and secondary endpoints given that it has portrayed a 73%-75% reduction rate of vertebrae fractures. It is also showing a reduction of the incidence of clinical fractures, which commonly occur in postmenopausal women.

However, it missed out on one of the secondary endpoints, which is a 25% reduction rate compared to placebo in the risk of non-vertebral fractures. Executive vice president of Research and Development at Amgen Inc (NASDAQ:AMGN), Sean Harper, explains that a vertebral fracture, which is caused by osteoporosis, is life-threatening and that one in every two women over the age of 50 will experience an osteoporotic fracture.

amgen, logo, economy, symbol, deutschland, name, markenname, germany, emblem, berlin, icon, embleme, brand, german, company, marke

360b / Shutterstock.com

The FRAME Study

The 24-month study involved an analysis of results from 7,180 women who had a one year intake of monthly 210 mg subcutaneous injections of romosozumab or placebo. This intake would be followed by 12 months of open-label denosumab treatment for both arms. The results were positive from the group that received romosozumab compared to the placebo group.

The use of Romosozumab followed by denosumab had a 75% reduction in risk of vertebral fractures including the relative risk of new vertebral fracture unlike placebo followed by osteoporosis drug denosumab. However, chief medical officer and executive vice president of UCB, Iris Loew-Friedrich, is advocating for a deeper understanding of the results, which will help in sharpening the profile of romosozumab.

The drug is in a race with rival biotech Radius Health Inc (NASDAQ:RDUS), whose EU approval is also set by the end of the year. But it has a competitive edge given that its treatment is only once a month unlike that of Radius’ drug, which is injected daily. However, some analysts insist that of Radius may have a stronger effect.

Meanwhile, Amgen Inc (NASDAQ:AMGN)’s treatment has already hit its Phase III Bridge study primary endpoint of increasing bone mineral density of lumbar spine compared to placebo. The projected 2017 launch for romo has a consensus forecast of $650 million of revenue by 2020 even as UCB and Amgen plan to have its results discussed with global regulators as they both look forward to the 2016 filing.

Follow Amgen Inc (NASDAQ:AMGN)
Trade (NASDAQ:AMGN) Now!

Note: This article is written by Andy Parker and originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!